Background. We studied the potential neuroprotective effects of halothane and des¯urane, compared with the awake state, on infarct size following 2 h of intraluminal middle cerebral artery occlusion (MCAo) and 22 h of reperfusion.
halothane is maintained when the pericranial temperature is controlled. 3 At the present time, no study has been reported on the effects of des¯urane on histopathology following focal cerebral ischaemia. Nevertheless, iso¯urane and des¯urane improve neurological outcome following transient global cerebral ischaemia in rats 4 and des¯urane has been shown to attenuate the decrease in tissue oxygenation during transient middle cerebral artery occlusion (MCAo) in humans, as compared with thiopental. 5 The aim of this study was, therefore, to determine whether des¯urane could reduce focal ischaemic injury and to compare such potential reduction with that afforded by halothane. In this study we examined four groups of rats with temporary MCAo (2 h) followed by reperfusion with either des¯urane or halothane anaesthesia during the experimental preparation. For each anaesthetic, one group remained anaesthetized for the duration of MCAo, while the other recovered from the anaesthetic regime following MCAo. A complementary study was also performed to compare pericranial temperatures following ischaemia under halothane and des¯urane anaesthesia.
Materials and methods
Adult male Sprague±Dawley rats weighing 315 (35) g (R. Janvier breeding center, Le Genest-St-Isle, France) were used in the present study. The animals had free access to food and water in an animal room at constant temperature (22 (1)°C), humidity (55 (10)%) and with reversed light cycle. Experimental procedures conformed to the guidelines proposed in the Guide for the Care and Use of Laboratory Animals, and to the appropriate European directives and French national legislation.
Animal preparation
Animals were randomly selected to be anaesthetized with halothane (n=18) or des¯urane (n=18) always delivered in oxygen:nitrous oxide (30:70%). After tracheal intubation, the animals lungs were arti®cially ventilated (Harvard Apparatus 683, MA, USA). Throughout the preparation period (45 min), halothane and des¯urane concentrations were maintained at 1.5±1.6 and 11±12%, respectively, corresponding to 2.0 MAC. 6 7 A catheter was inserted into the right femoral artery for continuous monitoring of mean arterial pressure (MAP) and the periodic analysis of blood gases and pH (Ciba Corning M328, Essex, UK). The catheter was tunnelled subcutaneously and exteriorized at the neck for use in awake animals. The animals were maintained normothermic (37.5±38°C) using a feedback controlled heating blanket (Harvard Apparatus Limited, Edenbridge, UK) connected to a rectal probe.
Experimental protocol and design
MCAo was performed by insertion of an intraluminal ®lament (made of a terminal cylinder of melting glue, 2 mm long, diameter 0.38 mm, attached to a nylon thread, 0.22 mm in diameter) into the lumen of the right external carotid artery. The ®lament was advanced into the internal carotid artery, 9 mm after the outer table of the skull and then secured to the external carotid artery. 8 In this manner, the terminal cylinder is reproducibly placed at the MCA origin. For each anaesthetic, the rats were then randomly assigned to one of two experimental groups, which differed by the duration of anaesthesia. Four experimental groups were studied (Fig. 1) .
Short-duration halothane: halothane anaesthesia was discontinued, the trachea was extubated and animals were allowed to spontaneously breathe air.
Long-duration halothane: anaesthesia was maintained with halothane 1.1±1.2% (1.5 MAC).
Short-duration des¯urane: des¯urane anaesthesia was discontinued and the trachea was extubated and again the animals were allowed to spontaneously breathe air.
Long-duration des¯urane: anaesthesia was maintained with des¯urane 8±9% (1.5 MAC).
During the period of ischaemia, the rats in the shortduration groups were allowed to move freely in the cage. Their body temperature was measured regularly by transiently inserting a rectal probe and was maintained with a heating lamp. After 2 h, these rats were re- The following day (24 h), infarcts were revealed by TTC staining. Four groups were studied which differed according to the anaesthetic drug used (halothane or des¯urane) and the duration of anaesthesia, as shown. All anaesthetics were delivered in oxygen:nitrous oxide (30:70%).
anaesthetized for about 10 min with the same anaesthetic as used previously to withdraw the ®lament. In all rats, the ®lament was then removed, wounds were sutured and anaesthesia was discontinued.
Twenty-two hours later, the animals were again anaesthetized with the same anaesthetic as used previously and perfused transcardially at 120 mm Hg with heparinized saline for 2 min followed by 2,3,5-triphenyltetrazolium chloride 2% (Sigma, Saint Quentin Fallavier, France) for 8 min. The brain was removed and ®xed by immersion in a paraformaldehyde solution 4%. The brain was then cut in 1 mm slices using a purpose made matrix. The slices were digitized. Infarcted regions were delineated using the public domain ImageJ software. The volume of infarction was calculated by integration over the whole brain of the infarcted surfaces.
In additional experiments, pericranial temperature was measured continuously with a probe inserted between the skull and the temporal muscle in rats exposed to the same protocol as that of long-duration halothane (n=5) and longduration des¯urane (n=5) groups.
Statistical analysis
Values are given as mean (SD). Data were analyzed by ANOVA using Statview â software (Abacus Concepts, Berkeley, CA, USA) as detailed in the results section followed when appropriate by a two-tailed Student's t-test. P<0.05 or P<0.05/number of comparisons (Bonferroni correction) was accepted as signi®cant.
Results

Volume of infarction
In all animals, an infarct was observed which comprised both the cortex and the striatum (Fig. 2) . Infarct volumes in the four groups are summarized in Figure 3 . The infarct volumes were compared by a two-way ANOVA (anaesthetic, duration), showing that there was no signi®cant interaction (P=0.16). However, the hypothesis of an interaction was not rejected as the power of the analysis was low (power <0.28). Student's t-tests with Bonferroni correction were then performed. In the halothane groups, a signi®cant reduction of infarct volume (31%; P<0.0047) was obtained in the long-duration halothane group (199 (54) mm 3 ) as compared with the short-duration halothane group (288 (61) mm 3 ). Similarly, for des¯urane, a reduction of infarct volume (55%; P<0.0001) in the long-duration des¯urane group as compared with the short-duration des¯urane group was found (121 (55) and 269 (71) mm 3 , respectively). In the short-duration groups, the mean infarct volume in the des¯urane group was not signi®cantly different from that in the halothane group (P>0.56). In the long-duration groups, the mean infarct volume in the des¯urane group was signi®cantly lower (39%) than that in the halothane group (P<0.0053).
Physiological parameters
Blood samples were obtained before ischaemia, and 45 and 90 min after MCAo. As detailed there was no difference between groups for Pa CO 2 at all times. For Pa O 2 , pH, and rectal temperature (Temp) there was no difference between the groups before ischaemia, with small but signi®cant changes during ischaemia.
Pa O 2 , Pa CO 2 , arterial pH, and Temp were analysed using a three-way repeated measures ANOVA (factors: anaesthetic, duration of anaesthesia, time as repeated factor). For Pa CO 2 and Temp, there were no signi®cant interactions and no main effects, except for Temp for which a signi®cant difference (0.2°C) between the short-duration and longduration groups was obtained (P=0.0003). For Pa O 2 and pH, interactions with time were found (P<0.03), and data obtained before and after MCAo were subsequently analysed separately. For these parameters, a three-way repeated measures ANOVA was performed on data obtained during ischaemia. No interaction (P>0.26) with time was found so that values obtained after MCAo were averaged.
Next, two-way factorial ANOVA (anaesthetic, duration) was performed before and after MCAo. All data and statistics are summarized in Table 1 . For Pa O 2 and pH, a signi®cant effect of the duration factor on pH was obtained (P<0.02). All other effects and interactions were not signi®cant. After MCAo, no signi®cant interaction was found for Pa O 2 (P>0.24) but the factors precluded some signi®cant effects (anaesthetic: P=0.0008; duration: P<0.0001). A signi®cant interaction is obtained (P<0.0008) for pH. Therefore, for each factor level, a Student's t-test was performed. All comparisons were signi®cant for pH (P<0.04) and the largest difference between the groups was 0.07 pH units.
Before ischaemia there was a signi®cant difference in MAP between halothane and des¯urane groups. During ischaemia, there was a signi®cant difference between the short-duration and long-duration groups at all times, but no effect of the anaesthetic (except for the ®rst 20 min after MCAo for the short-duration groups). Detailed analysis of MAP is presented below.
Continuous MAP recordings were averaged over 20 min periods (Fig. 4) . MAP was analysed by a three-way repeated measures ANOVA (anaesthetic, duration of anaesthesia, time). A second order interaction was found (P<0.0001) and hence a two-way factorial ANOVA was performed for each time. Before ischaemia, only the anaesthetic factor was signi®cant effect (P<0.022). For the ®rst time period after MCAo, a signi®cant interaction was obtained (P<0.0015). For both anaesthetics, a signi®cant effect was obtained for the duration factor (P<0.012). There was also a signi®cant difference between short-duration halothane and shortduration des¯urane groups (P=0.001). For all other times after MCAo, only the duration factor was signi®cant (P<0.0001).
For pericranial temperature, a two-way repeated measures ANOVA (factors: anaesthetic, time as repeated factor) was performed and no interaction was found (P>0.21). The anaesthetic had no signi®cant effect on pericranial temperature (P>0.18) with an average difference of 0.12°C (Fig. 5) . Physiological parameters (data not shown) were similar to those presented above.
Discussion
The results of the present study indicate that halothane and des¯urane induce neuroprotection against transient focal Although clinical evidence is lacking, volatile anaesthetics have been shown to provide neuroprotective effects against ischaemia in various species and experimental models.
1±5 It has been shown that 1.4 MAC of halothane or sevo¯urane, as compared with the awake state, reduces infarct volume by approximately 72 and 57%, respectively, in rats exposed to 90 min of focal cerebral ischaemia. 2 In the same model, 1.0 MAC of halothane remains neuroprotective even when brain temperature is maintained in normothermic conditions. 3 Our results are in accordance with these ®ndings in that the long-duration administration of halothane 1.1±1.2% during ischaemia in the present study provided a signi®cant decrease in cerebral infarct volume in normothermic rats. Several experiments with iso¯urane have shown that this compound (0.5, 1.0 MAC) protects the brain in rat models of global ischaemia 4 9 but the protection against focal cerebral ischaemia is debatable. In comparison with nitrous oxide/fentanyl, iso¯urane 2.5% reduces infarct volume and the frequency of transient ischaemic depolarizations in a 2 h MCAo rat model. 1 It has been reported that 1.5 MAC iso¯urane delays but does not prevent cerebral infarction in rats subjected to a 70 min focal ischaemia. 10 Finally, in spontaneously hypertensive rats, infarct volume following 3 h of MCAo and 2 h of reperfusion in animals anaesthetized with iso¯urane were larger than those in animals anaesthetized with halothane.
11 Although des¯ur-ane improves neurological outcome following transient global cerebral ischaemia in rats 4 and increases tissue oxygenation during transient MCAo in humans, 5 no studies have been reported on the effects of des¯urane on histopathology following focal ischaemia.
Physiological parameters are unlikely to be responsible for the differences in infarct size observed between longduration and short-duration groups. Indeed, there was a signi®cantly higher MAP in the short-duration groups as compared with the long-duration groups. As acute increases in arterial pressure decrease brain injury, 12 one would expect smaller infarcts in the short-duration anaesthetized groups. The differences between groups concerning the other physiological parameters (i.e. Pa O 2 , Pa CO 2 , pH and rectal and pericranial temperatures) were minor and probably without any biological signi®cance. The decrease in infarct volume in the long-duration groups may, therefore, be reasonably attributed to the inhalation of nitrous oxide and/or the volatile anaesthetics.
Nitrous oxide has been reported to have no effect or to increase cerebral ischaemic damage. In a 2-h rat reversible MCAo model, nitrous oxide 70% does not modify infarct volume. 13 In a rat brain global ischaemia model, animals ventilated with nitrous oxide 70% and oxygen 30% (as compared with those ventilated with nitrogen 70% and oxygen 30%) had a worse outcome. 9 Other authors have shown that nitrous oxide 50% impairs electrophysiologic recovery after 3.5 min of hypoxia in rat hippocampal slices.
14 Therefore, in the present study, nitrous oxide is probably not responsible for the observed neuroprotection.
Volatile anaesthetics may decrease ischaemic damage by various mechanisms. First, volatile anaesthetics produce cerebral vasodilation. Halothane potently dilates intracerebral arterioles in the rat brain. 15 In dogs, both iso¯urane and sevo¯urane signi®cantly dilate pial arterioles, an effect mediated, at least in part, via activation of K + ATP channels. 16 In patients undergoing routine spinal surgery, sevo¯urane and iso¯urane produce a dose-dependent cerebral vasodilatory effect. 17 Considering that vasodilation might produce an increase in intra-ischaemic cerebral blood ow and an increased supply of oxygen and glucose, vasodilation by volatile anaesthetics could be neuroprotective. Secondly, 0.75 MAC halothane or iso¯urane reduces cerebral metabolic rate, an effect which accompanies an improved outcome from severe brain ischaemia in the rat. 18 Thirdly, volatile anaesthetics produce hypothermia which is in itself neuroprotective. 19 20 Such a mechanism does not apply to our present study as body temperature was controlled. However, we cannot rule out an effect on brain temperature.
Volatile anaesthetics have major effects on synaptic neurotransmission which may participate in their neuroprotective effects, given the well described deleterious effects of glutamate during ischaemia. 21 22 There is increasing evidence that general anaesthetics enhance GABA-mediated synaptic inhibition 23 and that they depress excitatory glutamate-mediated transmission. 24 In rat hippocampal brain slices, electrophysiological studies have shown that volatile anaesthetics depress glutamate transmission. 25 Volatile anaesthetics increase glutamate uptake as demonstrated in cultured astrocytes from the hippocampi of rat embryos exposed to en¯urane, iso¯urane, and sevo¯urane. 26 Furthermore, iso¯urane reduces both L-glutamate and NMDA-mediated calcium in¯ux in rat cortical brain slices. 27 Volatile anaesthetics modulate the activity of GABA A receptors by a direct action on the channel complex. 23 28 29 The block of voltage-dependent Na + channels by low concentrations of anaesthetics might have a signi®cant role for neuroprotection because this attenuates membrane depolarization initiating the removal of the magnesium block of the NMDA receptor. 30 Finally, halothane, en¯urane, and iso¯urane induce a dosedependent uncoupling of gap junctions in primary cultures of mouse striatal astrocytes. 31 This effect together with the effects on glutamate transmission, may partly explain why halothane inhibits spreading depression like-depolarizations following ischaemia, thus leading to a reduced infarct volume. 32 Our study shows that des¯urane reduces infarct volume following transient MCAo. Furthermore, this effect is greater than that induced by halothane. In our study, the concentration of halothane and des¯urane during the preparation and focal cerebral ischaemia were equipotent. Therefore, the higher neuroprotection of des¯urane cannot be attributed to the difference in the applied anaesthetic concentrations for the two agents.
In other respects, changes in pericranial temperature by volatile anaesthetics may in¯uence infarct volume. When brain temperature is controlled, iso¯urane 0.7% does not protect the rat brain from 75 min intraluminal MCAo. 21 In contrast, the neuroprotection induced by halothane is maintained when pericranial temperature is controlled. 3 Pericranial temperature correlates well with brain temperature. 33 In our study, no signi®cant difference in pericranial temperature under des¯urane or halothane was found and the average difference was approximately 0.12°C. Therefore, in our study, the non-signi®cant changes in brain temperature are probably not responsible for the higher neuroprotection conferred by des¯urane.
The increase in brain tissue partial oxygen pressure and decrease in brain acidosis induced by des¯urane may participate in its neuroprotective effect during MCAo. 5 Although des¯urane possesses most of the properties of the other volatile anaesthetics discussed above, it also induces a concentration-dependent biphasic effect on sympathetic activity. Indeed, with concentrations of des¯urane under 6%, sympathetic activity is increased, while des¯urane decreases sympathetic activity at higher concentrations. 34 Thus, given the concentrations used in the present study, it may be assumed that des¯urane reduces sympathetic activity and catecholamine release. In this respect, Engelhard and colleagues 4 demonstrated that the neurological improvement induced by des¯urane following global ischaemia was associated with a reduction in sympathetic activity and catecholamine release. Several studies have addressed the effects of catecholamines in cerebral ischaemia. In a rat model of incomplete ischaemia, ganglionic block decreases plasma catecholamine concentrations and improves neurologic outcome. 35 In addition, neurologic outcome and stroke-related mortality were worse in rats with increased plasma epinephrine and norepinephrine concentrations compared with rats with ganglionic block. 36 Moreover, pre-ischaemic depletion of brain norepinephrine decreases infarct size and improves neurologic outcome in normothermic rats. 37 It is clear that sympathetic activity and adrenergic receptors modulate brain damage but the brain protection mechanisms suggested here against cerebral ischaemia remain largely unknown.
In conclusion, in our experimental methods, we have shown that des¯urane affords a more effective protection than halothane against transient focal cerebral ischaemia in rats. Although clinical evidence is lacking, numerous experimental studies support the hypothesis that volatile anaesthetics are neuroprotective following cerebral ischaemia.
